Date
2019Journal
Journal of Infectious DiseasesPublisher
Oxford University PressType
Letter
Metadata
Show full item recordIdentifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058569783&doi=10.1093%2finfdis%2fjiy436&partnerID=40&md5=1059eb08f0bc53e38e797654afd0e548; http://hdl.handle.net/10713/8539ae974a485f413a2113503eed53cd6c53
10.1093/infdis/jiy436
Scopus Count
Collections
Related articles
- Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
- Authors: Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M
- Issue date: 2015 Feb
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
- Authors: Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, extended SAILING Study Team
- Issue date: 2013 Aug 24
- Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.
- Authors: Malet I, Ambrosio FA, Subra F, Herrmann B, Leh H, Bouger MC, Artese A, Katlama C, Talarico C, Romeo I, Alcaro S, Costa G, Deprez E, Calvez V, Marcelin AG, Delelis O
- Issue date: 2018 May 1
- Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
- Authors: Theys K, Abecasis A, Libin P, Gomes PT, Cabanas J, Camacho RJ, Van Laethem K
- Issue date: 2015 Sep
- [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
- Authors: Moreno S, Berenguer J
- Issue date: 2015 Mar